ROCURONIUM 

1. Introduction

Rocuronium is a non-depolarizing neuromuscular blocking agent (NDNMBA) of the aminosteroid group.

 2. Classification

 3. Mechanism of Action

• Competitive antagonist at nicotinic acetylcholine receptors (Nm) at neuromuscular junction
• Prevents depolarization → flaccid paralysis

Sequence of paralysis:

1. Small muscles (eyes, face)
2. Limbs
3. Intercostals
4. Diaphragm (last)

Recovery → reverse order

4. Pharmacokinetics 

 Compared to vecuronium → faster onset

 5. Dosing (ICU & RSI)

 RSI Dose

• 1–1.2 mg/kg IV
  → Comparable onset to succinylcholine

 Maintenance / ICU infusion

• Bolus: 0.1–0.2 mg/kg
• Infusion: 5–12 µg/kg/min

 6. Indications in ICU

 Airway & Ventilation

• Rapid sequence intubation 
• Hyperkalemia risk
• Burns
• Neuromuscular disease
• Severe ARDS → ventilator synchrony
• Status asthmaticus (refractory)
• Raised ICP (prevents coughing/straining)

 Procedural

• Central line insertion (rarely)
• Imaging (MRI/CT if needed)

 7. Rocuronium vs Succinylcholine 

 Guideline shift:
Rocuronium increasingly preferred for RSI when sugammadex available

 8. Advantages in Critical Care

• Hemodynamically stable
• No histamine release
• No increase in ICP/IOP
• Safe in:
• Burns
• Neuromuscular disorders
• Hyperkalemia

 9. Adverse Effects

Common

• Prolonged paralysis (especially in ICU)
• ICU-acquired weakness (when prolonged use)

 Rare

• Anaphylaxis (higher risk among NMBAs )
• Tachycardia (mild)

10. Contraindications / Caution

• Severe hepatic dysfunction → prolonged action
• Obesity → dose based on ideal body weight (IBW)
• Myasthenia gravis → exaggerated effect

 11. Monitoring in ICU

Train-of-Four (TOF)

• Target: 1–2 twitches out of 4
• Prevents over-paralysis

Clinical endpoints

• Ventilator synchrony
• Absence of spontaneous breathing

12. Reversal 

 Sugammadex

• Specific reversal agent for aminosteroid NMBAs
• Encapsulates rocuronium → rapid reversal

 Advantage over neostigmine:

• Faster
• More predictable
• No cholinergic side effects